CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care
Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.
Read More
Ongoing Clinical Trials in the Metastatic CRPC Setting
Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.
Read More
Potential for CDK4/6 Inhibitors in Metastatic CRPC
Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.
Read More
Novel Therapeutic Targets in Metastatic CRPC
A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.
Read More
Metastatic CRPC: Novel Treatment Strategies With Radioligand Therapy
Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.
Read More
Radioligands in the Treatment of Metastatic CRPC: Radium-223
Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.
Read More
Radioligands in the Treatment of Metastatic CRPC: Lutetium-177–PSMA-617
Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.
Read More
Combination PARPi Strategies in Metastatic CRPC: Interpreting Data From Clinical Trials
Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.
Read More
Advent of PARP Inhibitors in Metastatic CRPC
Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.
Read More
Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer
Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.
Read More
Informing Systemic Therapy Selection With Negative Data in HSPC
A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.
Read More
What is the Role of Locoregional Therapy in Metastatic HSPC?
Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.
Read More
Systemic Treatment Armamentarium in Metastatic HSPC
Shared insight on the range of systemic therapy options available to patients who present with metastatic hormone-sensitive prostate cancer.
Read More
Overview of Metastatic HSPC: Diagnosis and Risk Stratification
Opening their first module on metastatic hormone-sensitive prostate cancer, panelists consider optimal diagnostic and risk stratification strategies for when a patient presents in clinic.
Read More